AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products Find AGTC on YouTube at goo.gl/sMdJqX.

MicroGenDX

MicroGenDX provides qPCR+NGS sequencing for the detection of infectious diseases. The American Medical Association (AMA) and Medicare have issued a billing code to MicroGenDX to provide this testing service, recognizing this technology as medically necessary. MicroGenDX is trusted by over 39,000 physicians worldwide and has helped over 900,000 patients with diagnostic testing for their chronic and life-threatening infections. MicroGenDX is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvements Amendments (CLIA) licensed clinical laboratory. Tens of thousands of patients with chronic and often life-threatening infections have benefited from MicroGenDX’s work. MicroGenDX's NGS technology offers several advantages over traditional culture-based methods for identifying microorganisms. It can detect a wider range of microorganisms, including those that are difficult to culture or grow in a laboratory. It also provides more accurate and comprehensive results, as it can detect multiple microorganisms in a single sample and identify them at the species or strain level. Additionally, NGS technology is faster than traditional methods, allowing for quicker diagnosis and treatment decisions.  MicroGenDX's testing services are used in a variety of settings, including hospitals, long-term care facilities, dental offices, and veterinary clinics. Their technology has been applied to a wide range of clinical conditions, including chronic wounds, orthopedic infections, respiratory infections, and urinary tract infections, among others.

Plasmidsaurus

We sequence whole plasmids, amplicons, whole bacterial genomes, and colonies overnight, without the need for primers and minipreps. Plasmidsaurus is on a mission to accelerate new cures and promote a healthier planet by unlocking new levels of productivity in scientists using DNA tools to bring their ideas to life. The company’s DNA sequencing services are used daily by thousands of innovators, including Nobel prize winners, dynamic biotech startups, pharmaceutical companies, research labs, and DIY biohackers. Plasmidsaurus’s global network of labs operates day and night to enable world-changing discoveries. Sequence Everything!

biomakers

BIOMAKERS es Centro de Medicina Genómica de Precisión y Biotecnología especializado en Análisis genómicos, Big Data y desarrollo de Tecnología para Oncología y otras áreas terapéuticas complejas en Latinoamérica y USA . Cuenta con Laboratorios Moleculares propios integrados en Argentina, Mexico y Brasil, en donde se llevan a cabo estudios de biomarcadores asociados al diagnóstico genómico-molecular y una Oficina de Big Data & Technology en San Francisco, USA. BIOMAKERS prioriza la innovación a partir de la incorporación de nuevas tecnologías a través de su departamento de I+D, y el desarrollo de Plataformas Tecnológicas con Inteligencia Artificial, junto con el desarrollo e implementación de nuevos estudios genéticos para 17 países de Latinoamérica, habiendo construido el BIOBANCO de tumores avanzados y el Dataset para cáncer más importante y grande de Latino América. BIOMAKERS está conformada por profesionales con amplia trayectoria en el ámbito científico, médico, de investigación clínica, y de desarrollo de tecnología quienes cuentan con lun expertise único en la región y conforman el grupo más experto de LATAM en Medicina de Precisión. BIOMAKERS se compromete con la comunidad, a través de políticas de responsabilidad social empresaria (RSE). Desde su fundación ha comenzado a trazar esta trayectoria, a través de campañas de difusión y capacitación de diversos entes sociales (proveedores, clientes, comunidad en general), así como también programas específicos de estudios genéticos en la población latinoamericana.

sdc (statistics & data corporation)

SDC delivers top-tier clinical trial services to pharmaceutical, biologic, and medical device/diagnostic companies since 2005. With industry leading strategic consulting and clinical biometrics solutions expertise at our core, our technology enabled services are fully scalable and supported via our diverse and complementary strategic partnerships to provide full service clinical trial solutions. Speak with us today to see why SDC Empowers Clinical Decisions.